CLDN18.2 protein (His tag)

Produktnummer ABIN7319933

Recombinant -Protein exprimiert in Escherichia coli (E. coli).

Kurzübersicht für CLDN18.2 protein (His tag) (ABIN7319933)

Target: CLDN18.2

Protein-Typ: Recombinant

Spezies: Human

Quelle: Escherichia coli (E. coli)

Reinheit: > 95 % as determined by reducing SDS-PAGE.

Produktdetails

Aufreinigungstag / Konjugat: His tag

Verwendungszweck: Recombinant Human CLDN18.2(N-6His,C-Avi)

Produktmerkmale: Biotinylated Recombinant Human CLDN18.2 is produced by our E.coli expression system and the targetgene encoding extracellular is expressed with a 6His tag at the N-terminus.

Endotoxin-Niveau: < 1.0 EU per g as determined by the LAL method.

Biological Activity Comment: Test in progress

Anwendungsinformationen

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Frozen, Liquid

Buffer: Supplied as a 0.2 μm filtered solution of 20 mM Tris, 8M Urea,150 mM NaCl, 5 mM β-ME, pH 8.5.

Lagerung: -20 °C

Informationen zur Lagerung: Store at < -20°C, stable for 6 months. Please minimize freeze-thaw cycles.

Antigendetails

Target: CLDN18.2

Hintergrund:

Background: Claudin-18(CLDN18) is a protein that in humans is encoded by the CLDN18 gene. It belongs to the group of claudins. CLDN18 belongs to the large claudin family of proteins, which form tight junction strands in epithelial cells. CLDN18 plays a major role in tight junction-specific obliteration of the intercellular space, through calcium-independent cell-adhesion activity. CLDN18 has two isoform A1 and isoform A2.IMAB362 (Claudiximab) is a monoclonal antibody against isoform 2 of Claudin-18. It is underinvestigation for the treatment of gastrointestinal adenocarcinomas and pancreatic tumors. IMAB362 was developed by Ganymed Pharmaceuticals AG.

Synonym: Claudin-18.2, CLDN18

Molekulargewicht: 12.6 kDa